# US 8,278,279 B2 · Method for treating prostatitis utilizing modified pore-forming protein proaerolysin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,279 B2
- Document ID: US8278279B2
- Status: Granted
- Kind: B2
- Application number: 13/139,928
- Filed: 2009-12-15
- Published: 2011-10-27
- Granted: 2012-10-02
- Earliest claimed: 2008-12-15
- Assignees: Protox Therapeutics, Inc.
- Inventors: J. Curtis Nickel
- Web page: https://patentgrep.com/patent/US8278279B2

## CPC

- C07K 14/195: from bacteria
- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 13/08: of the prostate
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.

## Claims

### Claim 1

A method of treating prostatitis in a subject, comprising administering to said subject a therapeutically effective amount of PRX302,
wherein the PRX302 comprises:
an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, and
an affinity tag.

### Claim 2 (depends on 1)

The method of claim 1, wherein the affinity tag is a polyhistidine tag.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polyhistidine tag includes six histidine residues.

### Claim 4 (depends on 1)

The method of claim 1, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intravenously, intraprostatically, intramuscularly, subcutaneously, or orally.

### Claim 5 (depends on 4)

The method of claim 4, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intravenously at 1 to 10 mg per 70 kg body weight.

### Claim 6 (depends on 4)

The method of claim 4, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intravenously at about3 mg per 70 kg body weight.

### Claim 7 (depends on 4)

The method of claim 4, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intraprostatically at 1 to 100 mg per 70 kg body weight.

### Claim 8 (depends on 7)

The method of claim 7, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intraprostatically at 25 to 30 mg per 70 kg body weight.

### Claim 9 (depends on 7)

The method of claim 7, wherein the PRX302 comprising an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag is administered intraprostatically at a volume equivalent to 20% of the prostate volume, at a fixed concentration of 3 μg/mL with the total dose being about 30 μg per gram prostate.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration results in a reduction in prostate volume.

### Claim 11 (depends on 10)

The method of claim 10, wherein administration results in at least a 10% reduction in prostate volume.

### Claim 12 (depends on 10)

The method of claim 10, wherein administration results in at least a 50% reduction in prostate volume.

### Claim 13 (depends on 1)

The method of claim 1, further comprising selecting a subject with at least one or more symptoms associated with prostatitis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the prostatitis is chronic prostatitis.

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering an additional therapeutic agent for treating prostatitis.

### Claim 16 (depends on 15)

The method of claim 15, wherein the additional therapeutic agent comprises an α-1-adrenoreceptor antagonist, an antibiotic, an anti-inflammatory agent, a 5α reductase inhibitor, a phytotherapy, or any combination thereof.

### Claim 17 (depends on 1)

The method of claim 1, further comprising selecting a subject with at least one or more signs associated with prostatitis.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more signs associated with prostatitis comprises a prostate volume of 30 to 100 mL, prostate specific antigen blood levels of 4-10 ng/mL, or a combination thereof.

### Claim 19 (depends on 3)

The method of claim 3, wherein the six histidine residues tag is at the C-terminal end of PRX302 (SEQ ID NO:4).

### Claim 20

A method of treating prostatitis in a subject, comprising administering to said subject a therapeutically effective amount of PRX302,
wherein the PRX302 comprises:
an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, and
a C-terminal polyhistidine tag that includes six histidine residues.
